Skip to main content
Jeevan Scientific Technology Limited logo

Jeevan Scientific Technology Limited — Investor Relations & Filings

Ticker · 538837 ISIN · INE237B01018 LEI · 8945008IEF6KI1KN0R09 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS 538837

About Jeevan Scientific Technology Limited

https://www.jeevanscientific.com/

Jeevan Scientific Technology Limited is a clinical research organization (CRO) providing comprehensive services to the global pharmaceutical and biopharmaceutical industries. The company specializes in clinical trial management, encompassing Phase I through IV studies, alongside specialized Bioavailability and Bioequivalence (BA/BE) research. Its service portfolio includes pharmacovigilance, clinical data management, medical writing, and regulatory affairs support. Operating from advanced clinical pharmacology units, the organization focuses on delivering high-quality data and ensuring compliance with international regulatory standards. By integrating scientific expertise with robust operational processes, the company assists clients in accelerating drug development timelines and navigating complex clinical development pathways.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for the Financial year ended 31st March,2026 as per Regulation 24 A of SEBI (Listing and Disclosure Requirements) Regulations, 2015(''Listing Regulations)
Regulatory Filings Classification · 87% confidence The document is an Annual Secretarial Compliance Report prepared by a Practicing Company Secretary under SEBI (LODR) Regulation 24A. It is submitted to the stock exchange as a regulatory compliance filing rather than a financial report (e.g., Annual or Interim Report), nor is it an audit of financial statements. It does not announce publication of another report but is itself a regulatory filing. Therefore, it best fits the "Regulatory Filings" category (RNS).
2026-05-29 English
Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.
Regulatory Filings Classification · 85% confidence The document is a compliance filing under SEBI Listing Obligations (Regulation 32) to BSE, providing the quarterly statement on deviation/variation in use of funds raised by preferential allotment. It does not contain full financial statements or result highlights and is not announcing a new report publication; rather, it is a regulatory disclosure. Thus it falls under General Regulatory Filings (RNS).
2026-05-29 English
Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditors of the Company for the FY 2026-27
Regulatory Filings Classification · 87% confidence The document is a stock exchange submission under SEBI Listing Regulations notifying the outcome of a board meeting, including audited financial results for the quarter and year ended 31 March 2026, the auditors’ report, internal auditor appointment, ESOP grants and share allotments. It is not a full Annual Report (10-K), nor a simple earnings release (ER), nor solely an interim report (IR) in the traditional sense but rather a mixed regulatory announcement containing officer certifications and compliance attachments. This fits the description of a general regulatory filing (RNS).
2026-05-29 English
Audited financial results for the quarter and year ended 31.03.2026
Interim / Quarterly Report Classification · 90% confidence The document is a regulatory filing to the stock exchange (BSE) containing detailed audited financial results for the quarter and year ended 31 March 2026, including profit & loss, balance sheet, cash flow statements and notes, plus the independent auditor’s report. It is not a full Annual Report (10-K) with narrative and corporate review, nor merely a summary Earnings Release (ER). It contains substantive financial statements for an interim period (quarter) and year-to-date, matching the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-29 English
Outcome of Board Meeting held on 29.05.2026
Interim / Quarterly Report Classification · 83% confidence The document is a SEBI Listing Reg. 30 disclosure titled “Outcome of Board Meeting” filed with the BSE. It includes the Board’s approval of the standalone and consolidated audited financial results for the quarter and year ended 31 March 2026, the auditors’ report with an unmodified opinion, and other board resolutions (internal auditor appointment, ESOP grants, share allotment). The filing contains full line‐item financial results (revenue, expenses, profit, EPS) rather than merely a summary or a notification of report publication. This matches our definition of an Interim/Quarterly Report (IR) because it presents substantive financial statements for a period shorter than (or ending with) the fiscal year. It is not a press‐style Earnings Release (ER), a full Annual Report (10‐K), nor a standalone Audit Report (AR). FY 2026
2026-05-29 English
Jeevan Scientific Technology Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Intimation of ....
Regulatory Filings Classification · 80% confidence The document is a notice of a Board Meeting to be held on May 29, 2026, filed pursuant to SEBI Listing Regulations. It does not announce a change in board composition, dividend, or publication of an actual report, nor does it contain financial data. It is a routine regulatory announcement required by the exchange. Therefore it falls under the general Regulatory Filings category (RNS).
2026-05-21 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.